BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 15550288)

  • 41. States respond to growing abuse of painkiller.
    Wasserman S
    State Legis; 2001; 27(9):33-4. PubMed ID: 11763873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Collegial support to improve prescription patterns for addictive preparations].
    von Hanno T; Hilberg E; Furuholmen D; Cramer G
    Tidsskr Nor Laegeforen; 1999 Jun; 119(17):2520-5. PubMed ID: 10425908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prescribing narcotics--fact and fiction against the background of the Dangerous Drugs Act].
    Sohn W
    MMW Fortschr Med; 2003 Mar; 145(13):40-1. PubMed ID: 15101532
    [No Abstract]   [Full Text] [Related]  

  • 44. Formulation considerations for the development of medications with abuse potential.
    Mansbach RS; Moore RA
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prescription drug abuse: an epidemic dilemma.
    DuPont RL
    J Psychoactive Drugs; 2010 Jun; 42(2):127-32. PubMed ID: 20648908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Searching for answers: proper prescribing of controlled prescription drugs.
    Brown ME; Swiggart WH; Dewey CM; Ghulyan MV
    J Psychoactive Drugs; 2012; 44(1):79-85. PubMed ID: 22641969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abuse of prescription drugs and the risk of addiction.
    Compton WM; Volkow ND
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S4-7. PubMed ID: 16563663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary in response to Paulozzi et al.: prescription drug abuse and safe pain management.
    Fishman SM
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):628-31. PubMed ID: 16862601
    [No Abstract]   [Full Text] [Related]  

  • 49. The dentist and prescription drug abuse.
    Balevi B; Breen L; Krasnowski J
    J Can Dent Assoc; 1996 Jan; 62(1):56-60. PubMed ID: 8673939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fifteen solutions to the problems of prescription drug abuse.
    Lurie P; Lee PR
    J Psychoactive Drugs; 1991; 23(4):349-57. PubMed ID: 1813607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of a good practice manual on professional practice associated with psychotropic PRN in acute mental health wards: an exploratory study.
    Baker JA; Lovell K; Harris N
    Int J Nurs Stud; 2008 Oct; 45(10):1403-10. PubMed ID: 18313059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
    Skurtveit S; Furu K; Kaasa S; Borchgrevink PC
    Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescription drug diversion: "what Lola wants, Lola gets".
    Thomison JB
    J Tenn Med Assoc; 1989 Jan; 82(1):35-7. PubMed ID: 2927111
    [No Abstract]   [Full Text] [Related]  

  • 54. The war on addiction.
    Alter J
    Newsweek; 2001 Feb; 137(7):36-9. PubMed ID: 11246719
    [No Abstract]   [Full Text] [Related]  

  • 55. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple schedule II prescriptions: the final rule.
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2008; 22(2):139-43. PubMed ID: 19042838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Medicaid Prescription Drug Initiative.
    Roslewicz TD
    NIDA Res Monogr; 1993; 131():200-5. PubMed ID: 8413531
    [No Abstract]   [Full Text] [Related]  

  • 58. Is the DEA's new "prescription series" regulation balanced?
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2008; 22(3):218-20. PubMed ID: 19042852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data.
    Parente ST; Kim SS; Finch MD; Schloff LA; Rector TS; Seifeldin R; Haddox JD
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):783-90. PubMed ID: 15623267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.